Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach

References

• ahrq.gov [homepage on the Internet]Medical Expenditure Panel Survey Publication DetailsUS Deaprtment of Health and Human Services2014 Available from: http://meps.ahrq.gov/mepsweb/data_stats/Pub_ProdResults_Details.jsp?pt=StatisticalBrief&opt=2&id=941Accessed August 6, 2014
   Google Scholar
• RonsleyRScottDWarburtonWPA population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011Can J Psychiatry201358636163923768264
   PubMed Web of Science ®Google Scholar
• MatoneMLocalioRHuangYSdosReisSFeudtnerCRubinDThe Relationship between Mental Health Diagnosis and Treatment with Second-Generation Antipsychotics over Time: A National Study of US Medicaid-Enrolled ChildrenHealth Serv Res20124751836186022946905
   PubMed Web of Science ®Google Scholar
• LaursenTMMunk-OlsenTVestergaardMLife Expectancy and Cardiovascular Mortality in Persons with SchizophreniaCurr Opin Psychiatry2012252838822249081
   PubMed Web of Science ®Google Scholar
• WildgustHJBearyMAre there Modifiable Risk Factors Which will Reduce the Excess Mortality in Schizophrenia?J Psychopharmacol201024Suppl 4375020923919
   PubMed Web of Science ®Google Scholar
• AcharyaTAcharyaSTringaliSHuangJAssociation of Antidepressant and Atypical Antipsychotic Use with Cardiovascular Events and Mortality in a Veteran PopulationPharmacotherapy201333101053106123776095
   PubMed Web of Science ®Google Scholar
• SaravaneDFeveBFrancesYAvec le soutien institutionnel du laboratoire Lilly [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]Encephale2009354330339 French19748369
   PubMed Web of Science ®Google Scholar
• ArnoldyRCurtisJSamarasKThe Effects of Antipsychotic Switching on Diabetes in Chronic SchizophreniaDiabet Med2014313e16e1924236701
   PubMed Web of Science ®Google Scholar
• BradfordDWCunninghamNTSlubickiMNAn Evidence Synthesis of Care Models to Improve General Medical Outcomes for Individuals With Serious Mental IllnessJ Clin Psychiatry2013748e754e76424021516
   PubMed Web of Science ®Google Scholar
• AyadRFAssarMDSimpsonLGarnerJBSchusslerJMCauses and management of drug-induced long QT syndromeProc (Bayl Univ Med Cent)201023325025520671821
   PubMedGoogle Scholar
• BazettHCAn analysis of the time-relations of electrocardiogramsHeart19207353370
   Google Scholar
• MolnarJZhangFWeissJEhlertFARosenthalJEDiurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular eventsJ Am Coll Cardiol199627176838522713
   PubMed Web of Science ®Google Scholar
• YapYGCammAJDrug induced QT prolongation and torsades de pointesHeart200389111363137214594906
   PubMed Web of Science ®Google Scholar
• RodenDMDrug-induced prolongation of the QT intervalN Engl J Med2004350101013102214999113
   PubMed Web of Science ®Google Scholar
• HollisterLEKosekJCSudden Death During Treatment With Phenothiazine DerivativesJAMA19651921035103814293499
   PubMed Web of Science ®Google Scholar
• CancroRWilderRA Mechanism of Sudden Death in Chlorpromazine TherapyAm J Psychiatry197012733683715458604
   PubMed Web of Science ®Google Scholar
• MooreMTBookMHSudden Death in Phenothiazine TherapyPsychiatr Q19704433894025514886
   PubMed Web of Science ®Google Scholar
• DenvirMASoodADowRBradyAJRankinACThioridazine, diarrhoea and torsades de pointeJ R Soc Med19989131451479659329
   PubMed Web of Science ®Google Scholar
• GlassmanAHBiggerJTJrAntipsychotic Drugs: Prolonged QTc Interval, Torsade De Pointes, and Sudden DeathAm J Psychiatry2001158111774178211691681
   PubMed Web of Science ®Google Scholar
• KongsamutSKangJChenXLRoehrJRampeDA Comparison of the Receptor Binding and HERG Channel Affinities for a Series of Antipsychotic DrugsEur J Pharmacol20024501374112176106
   PubMed Web of Science ®Google Scholar
• ThomasSHDrugs, QT Interval Abnormalities and Ventricular ArrhythmiasAdverse Drug React Toxicol Rev1994132771027918900
   PubMedGoogle Scholar
• RayWAChungCPMurrayKTHallKSteinCMAtypical Antipsychotic Drugs and the Risk of Sudden Cardiac DeathN Engl J Med2009360322523519144938
   PubMed Web of Science ®Google Scholar
• omh.ny.gov [homepage on the Internet]LiebermanJAMerrillDParameswaranSAPA Council on ResearchAPA Guidance on the use of Antipsychotic Drugs and Cardiac Sudden Death Available from: https://www.omh.ny.gov/omhweb/advisories/adult_antipsychotic_use_attachement.htmlAccessed May 13, 2014
   Google Scholar
• ManuPKaneJMCorrellCUSudden Death in Psychiatric PatientsJ Clin Psychiatry201172793694121672496
   PubMed Web of Science ®Google Scholar
• ZhangYPostWSBlasco-ColmenaresEDalalDTomaselliGFGuallarEElectrocardiographic QT interval and mortality: a meta-analysisEpidemiology201122566067021709561
   PubMed Web of Science ®Google Scholar
• OzekiYFujiiKKurimotoNQTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201034240140520079791
   PubMed Web of Science ®Google Scholar
• GirardinFRGex-FabryMBerneyPShahDGaspozJMDayerPDrug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry studyAm J Psychiatry2013170121468147624306340
   PubMed Web of Science ®Google Scholar
• SumićJCBarićVBilićPHercegMSisek-SpremMJukićVQTc and psychopharmacs: are there any differences between monotherapy and polytherapyAnn Gen Psychiatry200761317477877
   PubMedGoogle Scholar
• RabkinSWAging Effects on QT Interval: Implications for Safety of antipsychotic drugsJ Geriatr Cardiol2014111202524748877
   PubMed Web of Science ®Google Scholar
• CorrellCUHarrisJFigenVKaneJMManuPAntipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control studyJ Child Adolesc Psychopharmacol201121436536821823910
   PubMed Web of Science ®Google Scholar
• JohnsenEAanesenKSriskandarajahSKrokenRALøbergEMJørgensenHAQTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation AntipsychoticsSchizophr Res Treatment2013201337502024490070
   PubMedGoogle Scholar
• CurtisLHØstbyeTSenderskyVPrescription of QT- prolonging drugs in a cohort of about 5 million outpatientsAm J Med2003114213514112586234
   PubMed Web of Science ®Google Scholar
• psychiatryonline.org [homepage on the Internet]American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders2006 Available from: http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1665359Accessed May 13, 2014
   Google Scholar
• National Institute for Health and Care ExcellenceNICE Clinical Guideline 178: Psychosis and Schizophrenia in Adults: Treatment and ManagementNational Institute for Health and Care Excellence2014 Available from: http://www.nice.org.uk/nicemedia/live/14382/66534/66534.pdfAccessed May 13, 2014
   Google Scholar
• PurhonenMKoponenHTiihonenJTanskanenAOutcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohortPharmacoepidemiol Drug Saf201221111227123122941581
   PubMed Web of Science ®Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• StromBLEngSMFaichGComparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)Am J Psychiatry2011168219320121041245
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDrugsInformation for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate) Available from: http://www.fda.gov/Drugs/DrugSafety/ucm085203.htmAccessed May 13, 2014
   Google Scholar
• MuzykAJRayfieldARevolloJYHeinzHGagliardiJPExamination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidolDrug Saf201235754755322702639
   PubMed Web of Science ®Google Scholar
• ChungAKChuaSEEffects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysisJ Psychopharmacol201125564666620826552
   PubMed Web of Science ®Google Scholar
• PoluzziERaschiEKociAAntipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System databaseDrug Saf201336646747923553446
   PubMed Web of Science ®Google Scholar
• KaneJMLurasidone: a clinical overviewJ Clin Psychiatry201172Suppl 1242822217440
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-Induced Weight Gain: A Comprehensive Research SynthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• MitchellAJVancampfortDDe HerdtAYuWDe HertMIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsSchizophr Bull201339229530522927670
   PubMed Web of Science ®Google Scholar
• SaidMASulaimanAHHabilMHMetabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in MalaysiaSingapore Med J2012531280180723268153
   PubMed Web of Science ®Google Scholar
• Krane-GartiserKBreumLGlümrrCPrevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychoticsNord J Psychiatry201165534535221428861
   PubMed Web of Science ®Google Scholar
• HoltRIConsensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statementDiabetes Care20042782086208715277449
   PubMed Web of Science ®Google Scholar
• MitchellAJDelaffonVVancampfortDCorrellCUDe HertMGuideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practicesPsychol Med201242112514721846426
   PubMed Web of Science ®Google Scholar
• BarnesTRPatonCCavanaghMRHancockETaylorDMUK Prescribing Observatory for Mental HealthA UK audit of screening for the metabolic side effects of antipsychotics in community patientsSchizophr Bull20073361397140317483101
   PubMed Web of Science ®Google Scholar
• MorratoEHNewcomerJWKamatSBaserOHarnettJCuffelBMetabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetesDiabetes Care20093261037104219244091
   PubMed Web of Science ®Google Scholar
• HauptDWRosenblattLCKimEBakerRAWhiteheadRNewcomerJWPrevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated with Second-Generation Antipsychotic AgentsAm J Psychiatry2009166334535319147694
   PubMed Web of Science ®Google Scholar
• MalhotraAKCorrellCUChowdhuryNIAssociation between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gainArch Gen Psychiatry201269990491222566560
   PubMed Web of Science ®Google Scholar
• WardAQuonPAbouzaidSHaberNAhmedSKimECardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluationP T201338210911523599678
   PubMedGoogle Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazineArch Gen Psychiatry19884597897963046553
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• CitromeLKalsekarIBakerRAHebdenTA review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adultsCurr Med Res Opin20143081629164124666104
   PubMed Web of Science ®Google Scholar
• Aripiprazole [package insert]Rockville, MDOtsuka America Pharmaceutical, Inc2014 Available from: http://www.otsuka-us.com/Documents/Abilify.PI.pdfAccessed June 19, 2014
   Google Scholar
• Ziprazidone [package insert]New York, NYPfizer Inc2014 Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=584Accessed June 19, 2014
   Google Scholar
• Lurasidone [package insert]Marlborough, MASunovion Pharmaceuticals Inc2013 Available from: http://www.latuda.com/LatudaPrescrib-ingInformation.pdfAccessed June 19, 2014
   Google Scholar
• Paliperidone [package insert]Titusville, NJJanssen Pharmaceuticals, Inc2011 Available from: http://www.invega.com/prescribing-informationAccessed September 26, 2014
   Google Scholar
• Quetiapine [package insert]Wilmington, DEAstraZeneca2014 Available from: http://www1.astrazeneca-us.com/pi/seroquel.pdfAccessed June 19, 2014
   Google Scholar
• Risperidone [package insert]Titusville, NJJanssen Pharmaceuticals, Inc2014 Available from: http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdfAccessed June 19, 2014
   Google Scholar
• Asenapine [package insert]Whitehouse Station, NJMerck & Co2013 Available from: http://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdfAccessed June 19, 2014
   Google Scholar
• Iloperidone [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2014 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdfAccessed June 19, 2014
   Google Scholar
• Olanzapine [package insert]Indianapolis, INLilly USA, LLC2013 Available from: http://pi.lilly.com/us/zyprexa-pi.pdfAccessed June 19, 2014
   Google Scholar
• Clozapine [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2013 Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdfAccessed June 19, 2014
   Google Scholar
• CitromeLQuantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medicationsCurr Drug Saf20094322923719534647
   PubMedGoogle Scholar
• De HertMDetrauxJvan WinkelRYuWCorrellCUMetabolic and cardiovascular adverse effects associated with antipsychotic drugsNat Rev Endocrinol20118211412622009159
   PubMed Web of Science ®Google Scholar
• De HertMYuWDetrauxJSweersKvan WinkelRCorrellCUBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysisCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• EssockSMCovellNHDavisSMStroupTSRosenheckRALiebermanJAEffectiveness of switching antipsychotic medicationsAm J Psychiatry2006163122090209517151159
   PubMed Web of Science ®Google Scholar
• MaayanLCorrellCUManagement of antipsychotic-related weight gainExpert Rev Neurother20101071175120020586697
   PubMed Web of Science ®Google Scholar
• BakMFransenAJanssenJvan OsJDrukkerMAlmost all antipsychotics result in weight gain: a meta-analysisPLoS One201494e9411224763306
   PubMed Web of Science ®Google Scholar
• BaptistaTKinNMBeaulieuSde BaptistaEAObesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectivesPharmacopsychiatry200235620521912518268
   PubMed Web of Science ®Google Scholar
• DaumitGLDickersonFBWangNYA behavioral weight-loss intervention in persons with serious mental illnessN Engl J Med2013368171594160223517118
   PubMed Web of Science ®Google Scholar
• CabassaLJEzellJMLewis-FernándezRLifestyle interventions for adults with serious mental illness: a systematic literature reviewPsychiatr Serv201061877478220675835
   PubMed Web of Science ®Google Scholar
• MizunoYSuzukiTNakagawaAPharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysisSchizophr Bull Epub3172014
   Web of Science ®Google Scholar
• WuRRZhaoJPGuoXFMetformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled studyAm J Psychiatry2008165335235818245179
   PubMed Web of Science ®Google Scholar
• WuRRZhaoJPShaoPLifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trialJAMA2008299218519318182600
   PubMed Web of Science ®Google Scholar
• Romo-NavaFAlvarez-Icaza GonzálezDFresán-OrellanaAMelatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trialBipolar Disord201416441042124636483
   PubMed Web of Science ®Google Scholar
• NwosuBUMeltzerBMarandaLA potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychoticsJ Pediatr Endocrinol Metab2011249–1061962622145446
   PubMed Web of Science ®Google Scholar
• AndradeCPrimary prevention of cardiovascular events in patients with major mental illness: a possible role for statinsBipolar Disord201315881382324119211
   PubMed Web of Science ®Google Scholar
• De HertMKalnickaDvan WinkelRTreatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry200667121889189617194266
   PubMed Web of Science ®Google Scholar
• HanssensLDe HertMKalnickaDPharmacological treatment of severe dyslipidaemia in patients with schizophreniaInt Clin Psychopharmacol2007221434917159459
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJLichtensteinAH2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation201412925 Suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• McEvoyGKAHFS Drug Information^®56th edBethesda, MDAmerican Society of Health-System Pharmacists2014
   Google Scholar
• MeltzerHYColaPAParsaMMarked elevations of serum creatine kinase activity associated with antipsychotic drug treatmentNeuropsychopharmacology19961543954058887994
   PubMed Web of Science ®Google Scholar
• WalkerJLSmithGHGastonMSRobinsonCMSpontaneous compartment syndrome in association with simvastatin-induced myositisEmerg Med J200825530530618434476
   PubMed Web of Science ®Google Scholar
• PatierJLFerrereFMoreno-CoboMAEchanizARabdomiólisis producida por la asociación de sinvastatina y risperidona [Rhabdomyolysis caused by the association of simvastatin and risperidone]Med Clin (Barc)200712911439 Spanish17927942
   PubMed Web of Science ®Google Scholar
• GolombBAEvansMAStatin adverse effects: a review of the literature and evidence for a mitochondrial mechanismAm J Cardiovasc Drugs20088637341819159124
   PubMed Web of Science ®Google Scholar
• RichardsonKSchoenMFrenchBStatins and Cognitive Function: A Systematic ReviewAnn Intern Med20131591068869724247674
   PubMed Web of Science ®Google Scholar
• HaasSJHillRKrumHClozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003Drug Saf2007301475717194170
   PubMed Web of Science ®Google Scholar
• KilianJGKerrKLawrenceCCelermajerDSMyocarditis and cardiomyopathy associated with clozapineLancet199935491931841184510584719
   PubMed Web of Science ®Google Scholar
• [No authors listed]Quetiapine and cardiac muscle disordersPrescrire Int20132214018423951594
   PubMedGoogle Scholar
• RonaldsonKJFitzgeraldPBTaylorAJToplissDJMcNeilJJA new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controlsAust N Z J Psychiatry201145645846521524186
   PubMed Web of Science ®Google Scholar
• RonaldsonKJTaylorAJFitzgeraldPBToplissDJElsikMMcNeilJJDiagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controlsJ Clin Psychiatry201071897698120361910
   PubMed Web of Science ®Google Scholar
• ManuPSarpalDMuirOKaneJMCorrellCUWhen can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literatureSchizophr Res20121342–318018622113154
   PubMed Web of Science ®Google Scholar